Cargando…

Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results

This study aimed to evaluate the superoxide dismutase (SOD) activity of IgG in patients with schizophrenia. After signing informed consent, we included 67 patients with schizophrenia (34 people with acute schizophrenia and 33 individuals were on outpatient treatment in therapeutic remission) and 14...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mednova, Irina A., Smirnova, Liudmila P., Vasilieva, Alisa R., Kazantseva, Daria V., Epimakhova, Elena V., Krotenko, Nina M., Semke, Arkadiy V., Ivanova, Svetlana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503855/ https://www.ncbi.nlm.nih.gov/pubmed/36143234 http://dx.doi.org/10.3390/jpm12091449

Ejemplares similares

Superoxide dismutase activity of serum IgG in acute illness and remission period of schizophrenia
por: Mednova, I., et al.
Publicado: (2022)

IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects
por: Smirnova, Liudmila P., et al.
Publicado: (2020)

Different Directions of Effects of Polyclonal IgG Antibodies from Patients with Schizophrenia and Healthy Individuals on Cell Death In Vitro: A Pilot Study
por: Epimakhova, Elena V., et al.
Publicado: (2023)

The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia
por: Kamaeva, Daria A., et al.
Publicado: (2023)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Catalytic Antibodies in Bipolar Disorder: Serum IgGs Hydrolyze Myelin Basic Protein
por: Kamaeva, Daria A., et al.
Publicado: (2022)

Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
por: Parshukova, Daria A., et al.
Publicado: (2020)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

DNA-hydrolyzing catalytic IgGs from schizophrenia patients do not affect cell viability of the SH-SY5Y human neuroblastoma cell line
por: Epimakhova, E., et al.
Publicado: (2022)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2015)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
por: Ermakov, Evgeny A., et al.
Publicado: (2021)

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
por: Mednova, Irina A., et al.
Publicado: (2021)

Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients
por: Fattakhov, Nikolai, et al.
Publicado: (2018)

Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
por: Smirnova, Liudmila P., et al.
Publicado: (2021)

Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2017)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Proteomic profile of serum from patients with schizophrenia spectrum disorders
por: Dmitrieva, Elena, et al.
Publicado: (2022)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2020)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

Serum Growth Factors in Schizophrenia Patients
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review
por: Ermakov, Evgeny A., et al.
Publicado: (2023)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

The Role of Intravesicular Proteins and the Protein Corona of Extracellular Vesicles in the Development of Drug-Induced Polyneuropathy
por: Yunusova, Natalia V., et al.
Publicado: (2023)

Marker of schizophrenia with enduring negative symptoms
por: Dmitrieva, E., et al.
Publicado: (2022)

Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
por: Kozyrev, Evgeny A., et al.
Publicado: (2023)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

The difference in serum proteomes in schizophrenia and bipolar disorder
por: Smirnova, Liudmila, et al.
Publicado: (2019)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tlhgf7ejfb54ikeqplg62dvsmm